S

SSY Group Ltd
HKEX:2005

Watchlist Manager
SSY Group Ltd
HKEX:2005
Watchlist
Price: 3.01 HKD 3.44% Market Closed
Market Cap: 8.9B HKD
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one SSY Group Ltd stock under the Base Case scenario is 5.23 HKD. Compared to the current market price of 3.01 HKD, SSY Group Ltd is Undervalued by 42%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Relative Value
Base Case
5.23 HKD
Undervaluation 42%
Relative Value
Price
S
Worst Case
Base Case
Best Case

Valuation Multiples

1.5
P/S
P/S
Price to Sales
1.5
vs History
98
vs Industry
60
Median 3Y
2
Median 5Y
2.1
Industry
2.4
Forward
1.4
More Details
8.4
P/E
P/E
Price to Earnings
8.4
vs History
96
vs Industry
42
Median 3Y
10.6
Median 5Y
12.3
Industry
21
Forward
7.4
More Details
18.1
P/OCF
P/OCF
Price to OCF
18.1
vs History
49
vs Industry
32
Median 3Y
15.3
Median 5Y
17.5
Industry
16.2
More Details
55.4
P/FCFE
P/FCFE
Price to FCFE
55.4
vs History
14
vs Industry
12
Median 3Y
28.5
Median 5Y
24.7
Industry
24
More Details
1.2
P/B
P/B
Price to Book Value
1.2
vs History
98
vs Industry
52
Median 3Y
1.8
Median 5Y
2
Industry
2
More Details
1.8
EV/S
EV/S
Enterprise Value to Sales
1.8
vs History
92
vs Industry
56
Median 3Y
2
Median 5Y
2.1
Industry
2.6
Forward
1.7
More Details
3.6
EV/GP
EV/GP
Enterprise Value to Gross Profit
3.6
vs History
71
vs Industry
59
Median 3Y
3.6
Median 5Y
3.9
Industry
5.1
More Details
5.9
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
5.9
vs History
98
vs Industry
42
Median 3Y
7.4
Median 5Y
8.2
Industry
12.6
Forward
5.9
More Details
7.8
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
7.8
vs History
87
vs Industry
44
Median 3Y
8.6
Median 5Y
9.8
Industry
16
Forward
7.1
More Details
21.6
EV/OCF
EV/OCF
Enterprise Value to OCF
21.6
vs History
38
vs Industry
30
Median 3Y
15.8
Median 5Y
18.7
Industry
14.4
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
5
Median 3Y
36.2
Median 5Y
44.5
Industry
17.6
More Details
1
EV/IC
EV/IC
Enterprise Value to IC
1
vs History
98
vs Industry
56
Median 3Y
1.3
Median 5Y
1.4
Industry
1.8
More Details

Multiples Across Competitors

Competitors Multiples
SSY Group Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
HK
SSY Group Ltd
HKEX:2005
8.9B HKD 1.5 8.4 5.9 7.8
US
Eli Lilly and Co
NYSE:LLY
676.4B USD 13.8 60.9 32.8 35.9
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
367.9B USD 4.1 16.9 12.3 16.2
DK
Novo Nordisk A/S
CSE:NOVO B
2T DKK 6.8 19.5 12.9 14.6
CH
Roche Holding AG
SIX:ROG
206.7B CHF 3.4 25 9.4 11
CH
Novartis AG
SIX:NOVN
181.7B CHF 4.1 17.1 10.1 13.5
UK
AstraZeneca PLC
LSE:AZN
161.8B GBP 4 28.2 130.8 197.2
US
Merck & Co Inc
NYSE:MRK
195.2B USD 3.1 11.2 8.4 10.1
IE
Endo International PLC
LSE:0Y5F
163.5B USD 70.5 -56 261.3 655.3
US
Pfizer Inc
NYSE:PFE
132.6B USD 2.1 16.8 7.3 10.2
P/E Multiple
Earnings Growth PEG
HK
S
SSY Group Ltd
HKEX:2005
Average P/E: 22.7
8.4
14%
0.6
US
Eli Lilly and Co
NYSE:LLY
60.9
50%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
16.9
27%
0.6
DK
Novo Nordisk A/S
CSE:NOVO B
19.5
18%
1.1
CH
Roche Holding AG
SIX:ROG
25
32%
0.8
CH
Novartis AG
SIX:NOVN
17.1
17%
1
UK
AstraZeneca PLC
LSE:AZN
28.2
36%
0.8
US
Merck & Co Inc
NYSE:MRK
11.2
17%
0.7
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -56 N/A N/A
US
Pfizer Inc
NYSE:PFE
16.8
30%
0.6
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
HK
S
SSY Group Ltd
HKEX:2005
Average EV/EBITDA: 394.3
5.9
3%
2
US
Eli Lilly and Co
NYSE:LLY
32.8
30%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
12.3
7%
1.8
DK
Novo Nordisk A/S
CSE:NOVO B
12.9
13%
1
CH
Roche Holding AG
SIX:ROG
9.4
5%
1.9
CH
Novartis AG
SIX:NOVN
10.1
5%
2
UK
AstraZeneca PLC
LSE:AZN
130.8
10%
13.1
US
Merck & Co Inc
NYSE:MRK
8.4
8%
1
IE
E
Endo International PLC
LSE:0Y5F
261.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.3
2%
3.6
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
HK
S
SSY Group Ltd
HKEX:2005
Average EV/EBIT: 1 697.7
7.8
15%
0.5
US
Eli Lilly and Co
NYSE:LLY
35.9
33%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
16.2
13%
1.2
DK
Novo Nordisk A/S
CSE:NOVO B
14.6
14%
1
CH
Roche Holding AG
SIX:ROG
11
6%
1.8
CH
Novartis AG
SIX:NOVN
13.5
10%
1.4
UK
AstraZeneca PLC
LSE:AZN
197.2
21%
9.4
US
Merck & Co Inc
NYSE:MRK
10.1
12%
0.8
IE
E
Endo International PLC
LSE:0Y5F
655.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.2
10%
1

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 256,800+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.